Trial reportArchives of dermatology2012
A pilot study of an oral phosphodiesterase inhibitor (apremilast) for atopic dermatitis in adults.
Trial report in Archives of dermatology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01393158 (A Pilot Study of an Oral Phosphodiesterase Inhibitor), which is not on this map. Cited by 54 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Pilot Study of an Oral Phosphodiesterase Inhibitor (Apremilast) for Atopic Dermatitis in Adults
Who cites it
54 citing papers in PubMed, 2 syntheses or guidelines pooled it, 166 citations in OpenAlex.
- Efficacy of topical and systemic treatments for atopic dermatitis on pruritus: A systematic literature review and meta-analysis.Frontiers in medicine · 2022Pooled it
- Systemic treatments for eczema: a network meta-analysis.The Cochrane database of systematic reviews · 2020Pooled it
- Efficacy and safety of PDE4 inhibitor monotherapy in adult patients with atopic dermatitis: a systematic review and meta-analysis.Postepy dermatologii i alergologii · 2026Review
- Targeting Intracellular Pathways in Atopic Dermatitis with Small Molecule Therapeutics.Current issues in molecular biology · 2025Review
- The epidermal lipid-microbiome loop and immunity: Important players in atopic dermatitis.Journal of advanced research · 2025Review
- Exploring the Therapeutic Landscape: A Narrative Review on Topical and Oral Phosphodiesterase-4 Inhibitors in Dermatology.Pharmaceutics · 2025Review
- Apremilast treatment of immune-mediated inflammatory skin diseases: a narrative review.Frontiers in pharmacology · 2025Review
- Mechanisms and Recent Advances of Small-Molecule Therapeutics in Rosacea Treatment.Clinical, cosmetic and investigational dermatology · 2025Review
- Apremilast is a potentially useful treatment for severe palmoplantar pustulosis with extra-palmoplantar symptoms.Skin health and disease · 2024Article
- Pathomechanism of Pruritus in Psoriasis and Atopic Dermatitis: Novel Approaches, Similarities and Differences.International journal of molecular sciences · 2023Review
- The translational revolution in atopic dermatitis: the paradigm shift from pathogenesis to treatment.Cellular & molecular immunology · 2023Review
- The Dawn of a New Era in Atopic Dermatitis Treatment.Journal of clinical medicine · 2022Review
- Treatment Options for Troublesome Itch.Pharmaceuticals (Basel, Switzerland) · 2022Review
- Recent Developments and Advances in Atopic Dermatitis: A Focus on Epidemiology, Pathophysiology, and Treatment in the Pediatric Setting.Paediatric drugs · 2022Review
- Break on through: The role of innate immunity and barrier defence in atopic dermatitis and psoriasis.Skin health and disease · 2022Review
- Clinical Implication of Phosphodiesterase-4-Inhibition.International journal of molecular sciences · 2022Review
- Atopic dermatitis: an expanding therapeutic pipeline for a complex disease.Nature reviews. Drug discovery · 2022Review
- Evaluation of the Efficacy and Safety of Apremilast in the Management of Lichen Planus.Clinical, cosmetic and investigational dermatology · 2022Article
- Consensus Update for Systemic Treatment of Atopic Dermatitis.Annals of dermatology · 2021Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
objectiveTo investigate the preliminary safety and efficacy of apremilast, an oral phosphodiesterase 4 inhibitor, for atopic dermatitis.
designThis investigator-initiated, open-label pilot study evaluated 2 doses of apremilast in patients with atopic dermatitis. Differential gene analysis was performed from peripheral whole blood using data before and after treatment.
settingUniversity-based dermatology clinical research unit. PATIENTS: Sixteen adult patients with atopic dermatitis.
interventionA specific phosphodiesterase 4 inhibitor, apremilast.
main outcome measuresThe primary outcome was incidence of adverse events. Secondary outcomes included the differences in pruritus, Dermatology Life Quality Index (DLQI), and Eczema Area and Severity Index (EASI) scores between the baseline visit and end-ofstudy visit for each cohort.
resultsThe group receiving apremilast, 20 mg twice daily, displayed a significant reduction from baseline of pruritus (P=.02) and the DLQI (P=.003) at 3 months. The group receiving apremilast, 30 mg twice daily, displayed a significant reduction of the EASI (P=.008) and the DLQI (P=.01) at 3 months. At 6 months, there was a significant reduction of the EASI (P=.002), the visual analog scale (P=.03), and the DLQI (P=.03). Gene ontologic analyses comparing baseline with samples during treatment revealed alterations in immune response pathways, especially those related to cyclic adenosine monophosphate–mediated signaling.
conclusionsThese results support further development of apremilast for treatment of atopic dermatitis. Larger randomized controlled studies are needed to more adequately evaluate both safety and efficacy. Limitations include the small sample size and absence of a control.
trial registrationclinicaltrials.gov Identifier: NCT01393158.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.